Reports 9M 2024 net sales DKK 204.72B vs. DKK 166.4B last year. Lars Fruergaard Jorgensen, president and CEO, said: “We are pleased with the performance in the first nine months of 2024. The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before. Within R&D, we are very pleased about further read-outs across our semaglutide portfolio, including the SOUL trial in people living with diabetes and cardiovascular disease and the ESSENCE trial in people living with MASH.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Reports Strong Sales Growth in 2024
- Novo Nordisk Completes DKK 2.4 Billion Share Buyback
- AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports
- Biotech Alert: Searches spiking for these stocks today
- Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform